Hemoglobin and Hypertension: Clinical Implications and Management

Patient Management

The American Heart Association recommends controlling blood pressure according to contemporary hypertension guidelines, maintaining hematocrit <45% through phlebotomy, and adding low-dose aspirin 100 mg daily unless contraindicated in patients with Polycythemia Vera 1, 2, 3
The American College of Cardiology recommends targeting blood pressure <140/90 mm Hg for patients <60 years or with chronic kidney disease/diabetes, and <150/90 mm Hg for patients ≥60 years 6
The National Comprehensive Cancer Network recommends monitoring blood pressure in all patients receiving Erythropoiesis-Stimulating Agents (ESAs), particularly during initiation 4, 5
Approximately 23% of chronic kidney disease patients developed hypertension or increased blood pressure during ESA treatment, likely relating to underlying renal disease rather than hemoglobin elevation itself 5
Maintaining hematocrit strictly below 45% through therapeutic phlebotomy reduces cardiovascular death and major thrombotic events from 9.8% to 2.7% (hazard ratio 3.91) 1, 2, 3
Diuretic-based antihypertensive therapy, ACE inhibitors, ARBs, or beta blockers have been shown to prevent heart failure by approximately 50% 6, 7

Phlebotomy is indicated ONLY when hematocrit >65%, symptoms of hyperviscosity are present, patient is adequately hydrated, and no iron deficiency exists 1, 3
Routine phlebotomy in secondary erythrocytosis can worsen outcomes through iron deficiency 1, 3

Aggressively managing cardiovascular risk factors including smoking cessation, hypertension control, and diabetes management is recommended for all patients with elevated hemoglobin 1